Serum soluble interleukin-2 receptor levels are associated with clinical disease status and histopathological grade in non-Hodgkin's lymphoma and chronic lymphocytic leukemia.

Serum soluble Interleukin-2 receptor levels (sIL-2R) were measured in 121 patients (pts) with non-Hodgkin's lymphoma (NHL) and in 30 patients with Chronic lymphocytic leukemia (CLL). Sera collected from 32 normal volunteers and 18 patients with infection or a variety of non malignant hematological disorders served as controls. A small number of patients with Hairy cell leukemia (HCL) and Hodgkin's disease (HD) were also studied. NHL patients were classified according to their clinical status as "active" (82 pts) or "non-active" (39 pts) and CLL according to the stage of their disease. NHL patients were also further classified as low (55 pts), intermediate (38 pts) and high grade malignancy (28 pts), according to the Working formulation scheme. A significant difference was found between the high levels of sIL-2R in patients with "active" disease and the lower levels in patients with quiescent or responsive disease. Significantly different high levels were found in patients with aggressive (intermediate and high grade) lymphoma as opposed to low grade lymphoma and CLL. In CLL itself higher levels of sIL-2R were seen in more advanced disease than in early disease. Thirteen patients with active Hodgkin's disease (HD) had moderately elevated sIL-2R levels, similar to those recorded for patients with infections and some non-malignant hematological disorders while another 13 HD patients in remission, had normal levels comparable to those recorded in normal controls. Extremely high levels of sIL-2R were seen in 2 patients with HD with severe viral infections and levels approaching those seen in HCL, were noted (20-30,000 u/ml).(ABSTRACT TRUNCATED AT 250 WORDS)

[1]  V. Diehl,et al.  Low serum interleukin-2 receptor levels correlate with a good prognosis in patients with Hodgkin's lymphoma. , 1991, Annals of oncology : official journal of the European Society for Medical Oncology.

[2]  M. Ratain,et al.  Serum soluble interleukin-2 receptor is associated with clinical and pathologic disease status in hairy cell leukemia. , 1990, Blood.

[3]  H. Stein,et al.  Increased serum levels of soluble IL‐2 receptor, CD30 and CD8 molecules, and gamma‐interferon in angioimmunoblastic lymphadenopathy: possible pathogenetic role of immunoactivation mechanisms , 1990, British journal of haematology.

[4]  F. Menestrina,et al.  Serum levels of soluble interleukin‐2 receptor in hairy cell leukaemia: a reliable marker of neoplastic bulk , 1989, British journal of haematology.

[5]  T. Uchiyama,et al.  Elevated serum-soluble interleukin-2 receptor (Tac antigen) levels in chronic myelogenous leukemia patients with blastic crisis. , 1989, Blood.

[6]  F. Menestrina,et al.  Increased levels of soluble interleukin-2 receptor in non-Hodgkin's lymphomas. Relationship with clinical, histologic, and phenotypic features. , 1989, American journal of clinical pathology.

[7]  C. Pui.  Serum interleukin-2 receptor: clinical and biological implications. , 1989, Leukemia.

[8]  M. Chilosi,et al.  Origin of the soluble interleukin-2 receptor in the serum of patients with hairy cell leukemia. , 1988, Leukemia.

[9]  D. Longo,et al.  Elevated serum levels of soluble Tac peptide in adult T-cell leukemia: correlation with clinical status during chemotherapy. , 1988, Annals of internal medicine.

[10]  N. Kay,et al.  The malignant B cells from B-chronic lymphocytic leukemia patients release TAC-soluble interleukin-2 receptors. , 1988, Blood.

[11]  Jeffrey W. Clark,et al.  Serum soluble IL-2 receptor as a tumor marker in patients with hairy cell leukemia , 1988 .

[12]  F. Behm,et al.  Serum interleukin 2 receptor levels in childhood acute lymphoblastic leukemia. , 1988, Blood.

[13]  M. Matsuoka,et al.  Soluble interleukin 2 receptors in sera of Japanese patients with adult T cell leukemia mark activity of disease. , 1988, Blood.

[14]  M. Chilosi,et al.  THE SOLUBLE INTERLEUKIN‐2 RECEPTOR IN HAEMATOLOGICAL DISORDERS , 1987, British journal of haematology.

[15]  A. Scarpa,et al.  Soluble interleukin-2 receptors in the sera of patients with hairy cell leukemia: relationship with the effect of recombinant alpha-interferon therapy on clinical parameters and natural killer in vitro activity. , 1987, Blood.

[16]  C. Pui,et al.  High serum interleukin-2 receptor levels are related to advanced disease and a poor outcome in childhood non-Hodgkin's lymphoma. , 1987, Blood.

[17]  R. Foà,et al.  High serum levels of soluble interleukin 2 receptor in patients with B chronic lymphocytic leukemia. , 1987, Blood.

[18]  B. Edwards,et al.  Soluble interleukin-2 receptor levels in patients with undifferentiated and lymphoblastic lymphomas: correlation with survival. , 1987, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  S. Murphy,et al.  Lymphocyte interleukin 2 production and responsiveness are altered in patients with primary myelodysplastic syndrome. , 1987, Blood.

[20]  J. Lahuerta-Palacios,et al.  Soluble interleukin-2 receptors in B-cell leukemia and the acquired immunodeficiency syndrome. , 1987, Annals of internal medicine.

[21]  M. Lestani,et al.  Soluble interleukin-2 receptors in the serum of patients with Hodgkin's disease. , 1987, British Journal of Cancer.

[22]  R. Cotran,et al.  Interleukin 2 receptors are expressed by alveolar macrophages during pulmonary sarcoidosis and are inducible by lymphokine treatment of normal human lung macrophages, blood monocytes, and monocyte cell lines. , 1987, Journal of immunology.

[23]  T. Waldmann,et al.  The human interleukin-2 receptor: normal and abnormal expression in T cells and in leukemias induced by the human T-lymphotropic retroviruses. , 1986, Annals of internal medicine.

[24]  M. Chilosi,et al.  Detection of a Soluble form of the Receptor for Interleukin 2 in the Serum of Patients with Hairy Cell Leukaemia , 1986, The International journal of biological markers.

[25]  D. Nelson,et al.  Soluble interleukin 2 receptors are released from activated human lymphoid cells in vitro. , 1985, Journal of immunology.

[26]  T. Waldmann,et al.  Expression of interleukin 2 receptors on activated human B cells , 1984, The Journal of experimental medicine.

[27]  S. Fu,et al.  Detection and functional studies of p60-65 (Tac antigen) on activated human B cells , 1984, The Journal of experimental medicine.

[28]  G. Trinchieri,et al.  Response of resting human peripheral blood natural killer cells to interleukin 2 , 1984, The Journal of experimental medicine.

[29]  Mark J. Thomas,et al.  A new prognostic classification of chronic lymphocytic leukemia derived from a multivariate survival analysis , 1981, Cancer.

[30]  E. Cronkite,et al.  Clinical staging of chronic lymphocytic leukemia. , 1975, Blood.

[31]  H. Stein,et al.  High Serum Levels of Soluble Interleukin-2 Receptor and Absence of Detectable Levels of Soluble CD30 Molecule: A Specific Diagnostic Combination for Hairy Cell Leukemia , 1992 .

[32]  S. Pileri,et al.  Serum soluble interleukin-2 receptor levels in hairy cell leukemia: correlation with clinical and hematological parameters and with alpha-interferon treatment. , 1992, Leukemia & lymphoma.

[33]  E. Bosmans,et al.  Measurement of Soluble Interleukin 2 Receptor in Sera of Adult Patients with Hematological or Solid Malignancies. , 1991, Leukemia & lymphoma.

[34]  A. Ho,et al.  Activation of lymphocytes induced by recombinant human granulocyte-macrophage colony-stimulating factor in patients with malignant lymphoma. , 1990, Blood.